thebench.bio #1 Ecosystem for the Bio-Tech Industry

Clinical Daily Summary

Clinical Daily Summary: What Happened on October 11, 2026

Prime Medicine starts Wilson disease trial as Birmingham asthma service cuts waits

Prime dosed the first participant in a Wilson disease study. A hospital-Sanofi project increased severe-asthma biologic starts and reduced waits.

  • Updated
  • Read from 3 articles, 2 publications
  • P

Covers October 10 and October 11. There was no summary on October 10.

Today in brief

A participant has received Prime Medicine’s PM577a in a global Phase I/II trial for Wilson disease caused by the H1069Q mutation.1 At University Hospitals Birmingham, severe-asthma biologic starts rose from 51 to 174 across comparable 12-month periods after a Sanofi partnership project, while average waits fell from 196 days to 103.2

ProAxsis and Imperial College London are studying a rapid test for active neutrophil elastase during COPD exacerbations, with results expected in 2027.3

Prime Medicine starts dosing in Wilson disease study

Prime Medicine has dosed the first participant in a global Phase I/II study of PM577a for Wilson disease caused by the H1069Q mutation.1 Allen Reine expects clinical results from this program and Prime’s alpha-1 antitrypsin deficiency liver program in 2027.1

Birmingham project increased asthma biologic starts

Biologic treatment starts for severe asthma rose from 51 to 174 in comparable 12-month periods before and after University Hospitals Birmingham and Sanofi’s service project.2 Over the same comparison, average waits to start treatment fell from 196 days to 103.2

The partners funded an administrator to manage the biologics database, coordinate care and simplify patients’ routes to treatment.2 The service added a weekly biologic clinic. Within five months of the administrator starting, the Trust approved a business case to retain the role.2

COPD study tests rapid biomarker assay during exacerbations

ProAxsis and Imperial College London are evaluating a rapid point-of-care test for active neutrophil elastase in people experiencing chronic obstructive pulmonary disease (COPD) exacerbations.3 The 21-month collaboration is assessing whether the test can help identify what is driving an exacerbation, which symptoms alone may not reveal.3

The study’s results are expected in 2027.3 In a separate UK randomized trial, point-of-care C-reactive protein testing during COPD exacerbations reduced antibiotic use without worsening COPD health status.3

Also worth knowing

  • Japan’s PMDA accepted Nanoscope Therapeutics’ MOGENRY for priority review for inherited retinal dystrophies, with supporting data in retinitis pigmentosa and Stargardt disease.1

  • Cellares executive Fabian Gerlinghaus estimated that losing Bristol Myers Squibb’s manufacturing agreement could delay commercial production by about a year. The FDA selected Cellares for its PreCheck program.1

Also published